Published in Clin Cancer Res on December 01, 1999
Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy. Cancer Gene Ther (2010) 1.44
Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients. PLoS One (2008) 1.43
Gene regulatory and clinical effects of interferon β in patients with metastatic melanoma: a phase II trial. J Interferon Cytokine Res (2011) 0.82
Novel oncolytic viral therapies in patients with thoracic malignancies. Oncolytic Virother (2016) 0.78
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med (2001) 24.51
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med (2001) 11.88
A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med (2013) 6.67
A second specific endonuclease from Haemophilus aegyptius. J Mol Biol (1975) 6.36
Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol (2001) 4.97
The biology of chronic myeloid leukemia. N Engl J Med (1999) 4.80
Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia. N Engl J Med (1997) 3.62
The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med (1988) 2.93
Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making? Blood (1999) 2.79
Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia (2006) 2.66
Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood (2000) 2.53
Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest (2001) 2.21
Mycosis fungoides and Sezary syndrome. Blood (1996) 2.15
Sweet's syndrome and cancer. Clin Dermatol (1993) 1.88
Chronic myelogenous leukemia: biology and therapy. Ann Intern Med (1999) 1.87
Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med (1986) 1.86
Association of sebaceous gland tumors and internal malignancy: the Muir-Torre syndrome. Am J Med (1991) 1.82
Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma. Ann Intern Med (1997) 1.71
Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia. Neurology (1995) 1.71
Treatment of myelogenous leukemia: current status and investigational options. Blood (1996) 1.70
Malignancy-associated Sweet's syndrome: review of the world literature. J Clin Oncol (1988) 1.66
Comparison of competitive-nested PCR and real-time PCR in detecting BCR-ABL fusion transcripts in chronic myeloid leukemia patients. Leukemia (2002) 1.62
Sweet's syndrome: a neutrophilic dermatosis classically associated with acute onset and fever. Clin Dermatol (2000) 1.62
Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer (1988) 1.62
A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukaemia. Nature (1987) 1.61
Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood (1999) 1.57
Methylation of the ABL1 promoter in chronic myelogenous leukemia: lack of prognostic significance. Blood (1999) 1.55
Accurate quantitation of residual B-precursor acute lymphoblastic leukemia by limiting dilution and a PCR-based detection system: a description of the method and the principles involved. Leukemia (1995) 1.55
Physiology and pathophysiology of dendritic cells. Hum Pathol (1997) 1.54
Serum levels of interleukin-10 in patients with diffuse large cell lymphoma: lack of correlation with prognosis. Blood (1995) 1.52
Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol (1986) 1.50
Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia (2008) 1.49
Chronic neutropenia of childhood: frequent association with parvovirus infection and correlations with bone marrow culture studies. Br J Haematol (1993) 1.49
Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service. Ann Intern Med (1995) 1.48
Expression of p21ras in fresh primary and metastatic human colorectal tumors. Proc Natl Acad Sci U S A (1985) 1.47
Expression of glycolipid receptors to Shiga-like toxin on human B lymphocytes: a mechanism for the failure of long-lived antibody response to dysenteric disease. Int Immunol (1990) 1.45
Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation. J Clin Invest (1993) 1.43
Cost-effectiveness of interferon-alpha and conventional chemotherapy in chronic myelogenous leukemia. Ann Intern Med (1996) 1.43
Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood (2001) 1.43
The human cellular abl gene product in the chronic myelogenous leukemia cell line K562 has an associated tyrosine protein kinase activity. Virology (1985) 1.41
Chronic myelogenous leukemia: a concise update. Blood (1993) 1.40
Herpes simplex virus infections and cimetidine therapy. J Am Acad Dermatol (1988) 1.39
Sweet syndrome in patients with solid tumors. Cancer (1993) 1.38
A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients. J Clin Oncol (1988) 1.36
Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience. Ann Oncol (2012) 1.35
Recombinant human growth hormone in patients with HIV-associated wasting. A randomized, placebo-controlled trial. Serostim Study Group. Ann Intern Med (1996) 1.34
Chronic immune stimulation by sperm alloantigens. Support for the hypothesis that spermatozoa induce immune dysregulation in homosexual males. JAMA (1984) 1.31
Apoptosis. Molecules and mechanisms. Adv Exp Med Biol (1999) 1.30
Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma. J Clin Oncol (1995) 1.30
Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients. Am J Med (1987) 1.30
Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood (1989) 1.29
Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid. Leukemia (1999) 1.28
Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients. Ann Intern Med (1991) 1.28
Tripe palms and malignancy. J Clin Oncol (1989) 1.27
Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood (1998) 1.26
Homoharringtonine: history, current research, and future direction. Cancer (2001) 1.25
Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis. Blood (1998) 1.24
Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias. Leukemia (2004) 1.24
BAX and PKCalpha modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia. Clin Cancer Res (2000) 1.22
Caspase 2 and caspase 3 protein levels as predictors of survival in acute myelogenous leukemia. Blood (1998) 1.22
Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia. Leukemia (2010) 1.22
Expression of leukemia inhibitory factor and its receptor in breast cancer: a potential autocrine and paracrine growth regulatory mechanism. Breast Cancer Res Treat (1998) 1.20
BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance. Oncotarget (2013) 1.20
Sweet's syndrome and malignancy. Am J Med (1987) 1.18
Identification of molecular variants of p210bcr-abl in chronic myelogenous leukemia. Blood (1987) 1.18
Chronic myelogenous leukemia: a review. Am J Med (1996) 1.18
Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood (1995) 1.18
A new familial immunodeficiency disorder characterized by severe neutropenia, a defective marrow release mechanism, and hypogammaglobulinemia. Am J Med (1990) 1.17
Clinical investigation of human alpha interferon in chronic myelogenous leukemia. Blood (1987) 1.17
Muir-Torre syndrome. Dermatol Clin (1995) 1.17
Prognosis of chronic lymphocytic leukemia: a multivariate regression analysis of 325 untreated patients. Blood (1987) 1.15
Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia. Blood (1983) 1.15
2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia. Blood (1994) 1.14
Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J Clin Oncol (1991) 1.13
In vitro and in vivo effects of deferoxamine in neonatal acute leukemia. Blood (1987) 1.13
Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia. J Clin Oncol (1995) 1.11
Expression of the macrophage colony-stimulating factor and its receptor in gynecologic malignancies. Cancer (1991) 1.11
Thrombotic microangiopathy associated with interferon therapy for patients with chronic myelogenous leukemia: coincidence or true side effect? Cancer (1999) 1.11